Clinical trials: Thymoma, open to volunteers
Myasthenia Gravis
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
It is evidenced that efgartigimod can rapidly and significantly improve the symptoms of myasthenia gravis. The global multicenter clinical trials hace confirmed that efgartigimod is safe and well tolerated.
- Trial name
- NCT06221501
- Testing
- Efgartigimod Alfa
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Thymoma and Thymic Carcinoma, Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors.
- Conditions
- Thymoma and Thymic Carcinoma, Thymoma, Thymic Cancer, Thymic Epithelial Tumor
- Trial name
- NCT06692062
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Rongrong Zhou
Myasthenia Gravis, Thymoma
Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis
Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission, characterized by fluctuating muscle weakness and fatigue.
- Trial name
- NCT07853378
- Volunteers
- 30 people
- Sponsor
- Assiut University
Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Trial name
- NCT06402708
- Testing
- Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Fudan University
Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery.
- Conditions
- Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8
- Trial name
- NCT03295227
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Thymic Epithelial Tumor, Radiotherapy Side Effect
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection.
- Conditions
- Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
- Trial name
- NCT06311955
- Testing
- Carbon ion radiotherapy, combined with platinum-based regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
Thymic Epithelial Tumor, Recurrent Thymoma
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT05104736
- Testing
- PT-112
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Myasthaenia Gravis, Myasthenia
Myasthenia Gravis Foundation of America Global MG Patient Registry
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States.
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis
- Trial name
- MGFAPR (NCT06617741)
- Where
- United States
- Volunteers
- 3,800 people
- Sponsor
- Myasthenia Gravis Foundation of America
Untreated Advanced or Recurrent Thymic Carcinomas
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or…
- Trial name
- Artemis (NCT05832827)
- Testing
- MK-3475, Lenvatinib, Carboplatin
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan
Lung Cancer, Thoracic Cancer
Prospective Data Collection Initiative on Thoracic Malignancies
Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome.
- Conditions
- Lung Cancer, Thoracic Cancer, Lung Cancer, Nonsmall Cell, Adenocarcinoma
- Trial name
- DuTOC (NCT06996249)
- Testing
- Health-related quality of life and treatment outcome questionnaires, (Tumor) tissue and other biomaterials, Blood samples
- Where
- 23 sites in Netherlands
- Volunteers
- 12,000 people
- Sponsor
- Dutch Society of Physicians for Pulmonology and Tuberculosis
Thymoma
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
- Trial name
- NCT06730308
- Testing
- Radiotherapy, Concurrent chemotherapy, Methylprednisolone
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Thymoma
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.
- Trial name
- NCT02633553
- Testing
- adjuvant radiotherapy
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Fudan University
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy.
- Conditions
- Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
- Trial name
- LEVEL (NCT05918302)
- Testing
- 177Lu-edotreotide, Everolimus
- Where
- 27 sites in Belgium, France and 2 more
- Volunteers
- 170 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
To observe the efficacy of carbon ion radiotherapy combined with chemotherapy in the treatment of inoperable locally advanced or advanced (all visible lesions can be included in the radiation target area in this treatment)…
- Trial name
- NCT06186726
- Testing
- carbon ion radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Thymus Epithelial Tumor, Proton Radiotherapy
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies.
- Conditions
- Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
- Trial name
- NCT06311968
- Testing
- Proton radiotherapy, combined platinum based chemotherapy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Jian Chen
Cardiotoxicity, Pulmonary Toxicity
Study on Proton Radiotherapy of Thymic Malignancies
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e.
- Conditions
- Cardiotoxicity, Pulmonary Toxicity, Thymus Neoplasms
- Trial name
- PROTHYM (NCT04822077)
- Testing
- Proton radiation
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Ass. Prof. Jan Nyman
Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations…
- Trial name
- NCT06019468
- Testing
- Envolizumab combined with radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Thymic Carcinoma
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT.
- Trial name
- NCT07324629
- Testing
- Sacituzumab tirumotecan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Thymoma
Robot-assisted vs VATS for Thymoma
The aim of this study is to explore the advantages of robot-assisted thymectomy in long-term survival benefits and short-term clinical efficacy compared with video-assisted thoracoscopic thymectomy based on a multi-center…
- Trial name
- NCT06029621
- Testing
- RATS for Thymectomy, VATS for Thymectomy
- Where
- 2 sites in China
- Volunteers
- 304 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China